Browsing Tag
NNZ-2591
6 posts
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.
Neuren Pharmaceuticals (ASX: NEU) jumped 45% in two sessions, but how much DAYBUE upside remains?
DAYBUE’s EU breakthrough sent NEU up 45% in two sessions. The harder test is whether royalties and NNZ-2591 justify A$2.25 billion.
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.
Neuren Pharmaceuticals secures third FDA Fast Track for NNZ-2591 as shares rise 4.21%
Find out how Neuren Pharmaceuticals is expanding FDA Fast Track coverage for NNZ‑2591 across rare disorders like PMS, AS, and Pitt Hopkins.
Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the…
Neuren Pharmaceuticals achieves breakthrough in Pitt Hopkins syndrome treatment
Neuren Pharmaceuticals (ASX: NEU) has announced promising top-line results from its Phase 2 clinical trial of NNZ-2591, aimed…